Stocktoria
TALPHERA, INC. TLPH
TALPHERA, INC. (TLPH) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $28,000 at a -51035.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TLPH | TALPHERA, INC. | 4/9 | — | — | — |
| IBO | IMPACT BIOMEDICAL INC. | 3/9 | -2.38 | — | — |
| JUNS | JUPITER NEUROSCIENCES, INC. | 2/9 | — | — | — |
| LYEL | Lyell Immunopharma, Inc. | 1/9 | -13.93 | — | — |
| PRFX | PRF Technologies Ltd. | 4/9 | -14.88 | — | — |
| AXIM | AXIM BIOTECHNOLOGIES, INC. | 3/9 | — | — | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | 1/9 | — | — | — |
About TALPHERA, INC.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
FAQ
Is TLPH financially healthy?
TALPHERA, INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does TLPH pay a dividend?
No, TALPHERA, INC. does not currently pay a dividend.
How profitable is TLPH?
In FY2025, TALPHERA, INC. had a net margin of -51035.7% and a return on equity of -83.9%.
What is the analyst price target for TLPH?
The average Wall-Street price target for TALPHERA, INC. is $3.17, about 126.2% above the recent price, from 3 analysts.
Is TLPH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on TALPHERA, INC.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.